Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...

Financial Data and Key Metrics Changes - Worldwide revenue for the quarter reached $47.3 million, representing approximately 25% growth compared to the prior year [6][27] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][28] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7%, improving by nearly 80 basis points [28] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched last year [7][9] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [14] - The introduction of iFuse Torque and iFuse Intra has expanded the market and accelerated procedure volume growth [11][12] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with 25% cumulative procedure volume growth over the last three years [10][11] - The company is targeting nearly 100,000 degenerative procedures annually with the Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [14] - The pelvic trauma market, with nearly 60,000 potential target procedures annually, represents a $300 million market opportunity [18] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [10] - A hybrid commercial model combining territory managers and clinical specialists with third-party agents is being utilized to enhance market reach [25] - The company plans to launch new products over the next twelve to eighteen months, including a new SI joint fusion solution and a breakthrough device targeting spine surgery [19][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for solutions and the ability to maintain strong revenue growth despite macroeconomic uncertainties [32][56] - The company updated its full-year revenue guidance to a range of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [33][34] - Management highlighted the importance of favorable reimbursement trends and the potential for continued growth in procedure volumes [15][56] Other Important Information - The company exited the quarter with $144.4 million in cash and marketable securities, with a total cash usage of $5.6 million, a 31.7% improvement over the prior year [30] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth across all modalities, with strong demand for new products launched in 2024 contributing to accelerating growth [39] Question: Drivers of strong gross margin and future expectations - Management attributed gross margin improvement to better-than-expected average selling prices and supply chain efficiencies, while remaining cautious about potential pressures [42][46] Question: Long-term growth potential and guidance - Management expressed confidence in sustained growth potential beyond 2025, driven by technology leadership and expanding physician engagement [55] Question: Sequential growth expectations and guidance update - Management indicated that while they expect to maintain strong growth, they are being prudent in their guidance due to macroeconomic conditions [64] Question: Operating expenses and growth expectations - Management highlighted that increased operating expenses are linked to R&D investments and sales commissions, but they expect to maintain healthy operating leverage [70]

SI-BONE Corporate Overview May 2025 Forward-Looking Statements This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negati ...

Financial Data and Key Metrics Changes - Worldwide revenue for Q1 2025 reached $47.3 million, representing approximately 25% growth compared to the prior year [6][26] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][26] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7% [27] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [28] - Positive adjusted EBITDA of approximately $5 million compared to an adjusted EBITDA loss of $4 million in Q1 2024 [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched in 2024 [7][39] - The number of physicians performing procedures using the company's products grew by 27%, with over 1,400 U.S. physicians engaged [19] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [13] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with a cumulative procedure volume growth of 25% over the last three years [9][10] - The company is targeting nearly 100,000 degenerative procedures annually with its Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [13][14] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [9] - The strategy includes diversifying the product platform with unique yet complementary technologies to expand the target modalities and physician footprint [9][10] - The company aims to reach 100 territories over the next 12 to 15 months, leveraging a hybrid commercial model combining territory managers and third-party agents [24][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong results over the long term, supported by resilient business trends and favorable reimbursement conditions [8][9] - The updated full-year revenue guidance is between $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [32] - Management noted that the company is well-positioned to achieve free cash flow in 2026, with a focus on maintaining operational discipline [30][32] Other Important Information - The company has a strong pipeline of novel technologies under development, with plans to launch new products over the next 12 to 18 months [16][18] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [30][31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth and strong demand for current solutions, with impressive adoption of new products launched in 2024 [39] Question: Drivers of gross margin and future expectations - Management highlighted better-than-expected average selling price (ASP) and efficiency initiatives as key drivers of gross margin improvement [42][44] Question: Long-term growth expectations - Management expressed confidence in sustained growth potential, driven by technology leadership and expanding physician engagement [53][56] Question: Expected cadence of new guidance and sequential growth - Management indicated that while they do not think about the business in quarters, they expect to manage seasonality effectively with new product rollouts [66] Question: Operating expenses guidance - Management explained that elevated R&D investments and higher commissions linked to revenue growth are driving the expected increase in operating expenses [70][72] Question: Update on surgeon base and engagement - Management reported a record increase in the physician base, with broad engagement across various specialties [76][78] Question: Updates on reimbursement proposals - Management provided insights on CMS proposals and the potential for increased reimbursement rates, which could accelerate adoption of products [80][81] Question: Traction and adoption of TNT product - Management noted that TNT is seeing rapid adoption and is expected to benefit from upcoming reimbursement changes [97]

Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Recent Operational Highlights (any comparisons are to the prior year period) SANTA CLARA, Calif. May 5, 2025 - SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended March 31, 2025. "Our momentum continues unabated with a strong start to 2025, as we outperfo ...

Core Insights - SI-BONE, Inc. reported strong financial results for Q1 2025, with significant revenue growth and improved profitability metrics [3][4][7]. Financial Performance - Worldwide revenue reached $47.3 million, a 24.9% increase from $37.9 million in Q1 2024 [4][9]. - U.S. revenue was $44.8 million, reflecting a 26.6% increase from $35.4 million in the same period last year [4][9]. - Gross profit was $37.7 million, up 26.2% from $29.9 million in Q1 2024, with a gross margin of 79.7%, an improvement of 80 basis points [5][9]. - Operating expenses increased by 7.8% to $45.2 million, driven by higher commercial activity and R&D investments [6][9]. - Operating loss improved by 37.9% to $7.5 million, while net loss decreased by 40.0% to $6.5 million, or $0.15 per diluted share [7][9]. - Adjusted EBITDA was positive at $0.5 million, a significant improvement from an adjusted EBITDA loss of $4.0 million in Q1 2024 [8][9]. Operational Highlights - The company added over 300 active U.S. physicians in the quarter, totaling over 1,400, representing a 27.3% growth [9]. - The strong underlying procedure demand and the rollout of new products contributed to revenue growth [4][9]. Guidance and Outlook - SI-BONE updated its 2025 revenue guidance to a range of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [10][11]. - The company expects a gross margin of 78% for the full year and anticipates operating expenses to grow at around 10% [10][11].

Core Insights - SI-BONE, Inc. will report its financial results for Q1 2025 on May 5, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,300 physicians and performed over 115,000 procedures since 2009 [3] Company Overview - SI-BONE has pioneered minimally invasive SI joint surgery and has a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] - The company has expanded its offerings to adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma [3] Investor Information - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2] - The webcast will be archived for at least 90 days for replay [2]

2 Market Leader in the Sacropelvic Space SI-BONE Corporate Overview February 2025 Safe Harbor Statement This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and simi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (408) 207-0700 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its ...

Financial Data and Key Metrics Changes - The company reported a record $49 million in worldwide revenue for Q4 2024, representing growth exceeding 26% compared to the previous year [9][41] - U.S. revenue increased by 28% to $46.9 million, driven by strong demand from nearly 1,400 active physicians [10][41] - Gross profit for Q4 increased by 35% to $38.8 million, with a gross margin of 79% [43] - The net loss improved by nearly 60% to $4.5 million, or $0.11 per diluted share [45] - Positive adjusted EBITDA of $1.9 million was achieved in Q4, compared to an adjusted EBITDA loss of $4.8 million in Q4 2023 [46] Business Line Data and Key Metrics Changes - The SI joint fusion procedures saw a surge in demand, particularly with the adoption of the TORQ and INTRA products [11][24] - The Granite 9.5% product gained momentum, with a nearly 45% increase in stack granite volume compared to the prior year [26][32] - The newly launched TNT product exceeded expectations in adoption, indicating strong early demand [11][34] Market Data and Key Metrics Changes - The company ended 2024 with $150 million in cash and marketable securities, with total cash usage in Q4 being less than $800,000 [47] - International revenue for Q4 was $2.1 million, with full-year international revenue at $8.8 million [42] Company Strategy and Development Direction - The company aims to implement targeted commercial initiatives to fuel adoption of its expanded portfolio and grow its physician base [13] - Plans to increase procedure density through multimodality physician engagement and lay groundwork for commercialization of new products [14] - The company is focused on maintaining its leadership position in the market through innovation and strategic partnerships [17][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong revenue growth and profitability in 2025, driven by robust procedure demand and a growing physician base [48][51] - The company anticipates worldwide revenue of $193.5 million to $195.5 million in 2025, implying year-over-year growth of approximately 16% to 17% [49] - Management highlighted the importance of clinical publications in accelerating adoption and maintaining differentiated reimbursement [38] Other Important Information - The company is cooperating with the Department of Justice (DoJ) regarding an ongoing investigation, with no material updates expected prior to resolution [39][135] - The company has been awarded breakthrough device designation for a new novel implant system, positioning it as a category creator in the industry [36][100] Q&A Session Summary Question: Growth drivers for the company - Management noted strong momentum across all procedure types, with significant contributions from SI joint fusion, Granite 9.5%, and TNT products [56][58] Question: Guidance for 2025 growth - Management provided a balanced approach to guidance, incorporating assumptions about ASP decline and one less procedure day in the year [62][66] Question: Competitive landscape - Management expressed confidence in maintaining market leadership, supported by a comprehensive product portfolio and strong educational initiatives [71][72] Question: Update on Granite NTAP - Management confirmed that they have submitted an application to CMS for a higher paying code for Granite, with updates expected mid-year [111] Question: Profit ramp cadence through 2025 - Management expects to be adjusted EBITDA positive in the second half of 2025, with a focus on maintaining operating leverage [117][121]